Matinas BioPharma Holdings, Inc.
MTNBDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Omega 3 pentaenoic acid
Hypertriglyceridemia
Drug Omega 3
Hypertriglyceridemia
Amphotericin B
Candidiasis, Chronic Mucocutaneous
MAT2203
Cryptococcal Meningitis
Oral Encochleated Amphotericin B (CAMB)
Vulvovaginitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Omega 3 pentaenoic acid | Phase 2 | Hypertriglyceridemia | - | - |
Drug Omega 3 | Phase 2 | Hypertriglyceridemia | - | - |
Amphotericin B | Phase 2 | Candidiasis, Chronic Mucocutaneous | - | - |
MAT2203 | Phase 2 | Cryptococcal Meningitis | - | - |
Oral Encochleated Amphotericin B (CAMB) | Phase 2 | Vulvovaginitis | - | - |
Frequently asked questions
What is in Matinas BioPharma Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Matinas BioPharma Holdings, Inc.'s (MTNB) pipeline across Phase 2. Its lead program is Omega 3 pentaenoic acid (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Matinas BioPharma Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Matinas BioPharma Holdings, Inc. (MTNB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MTNB biotech catalysts?→
Add MTNB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Matinas BioPharma Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.